Quantum BioPharma Ltd. announced that its licensee, Unbuzzd Wellness Inc., will host an investor webinar on October 30, 2025, as part of its Regulation D 506(c) offering seeking to raise up to $5 million. This funding round is structured to avoid dilution to Quantum BioPharma shareholders, making it an important financial development for current investors. The webinar will feature Unbuzzd CEO John Duffy, Advisor Jason Sawyer, Medical Director Dr. Eric Hoskins, and Board Co-Chair Gerry David, the former CEO of Celsius, who will discuss the investment opportunity and company strategy.
The significance of this announcement extends beyond the immediate fundraising effort. Unbuzzd Wellness is commercializing unbuzzd(TM), a scientifically proven beverage that accelerates alcohol metabolism, restores mental clarity, and reduces hangover symptoms. This represents a meaningful advancement in consumer health products that address alcohol-related issues through scientific innovation. The product's development stems from Quantum BioPharma's research capabilities, demonstrating how biopharmaceutical companies can spin out consumer health applications from their core research.
Quantum BioPharma retains substantial financial interest in Unbuzzd Wellness through its 20.11% ownership stake and royalty agreement that provides 7% of sales until payments total $250 million, then 3% in perpetuity. This structure creates long-term value for Quantum BioPharma shareholders while allowing Unbuzzd to operate independently. The arrangement also preserves Quantum BioPharma's rights to develop similar products for pharmaceutical and medical uses, maintaining strategic flexibility in both consumer and medical markets.
The investor webinar represents a critical step in bringing this innovative product to market. Participants will learn about leadership strategy and distribution plans for unbuzzd(TM), providing insight into how the company plans to commercialize this scientifically-backed beverage. The inclusion of industry veterans like former Celsius CEO Gerry David adds credibility to the venture and suggests potential for significant market penetration. Additional information about Quantum BioPharma is available in the company's newsroom at https://ibn.fm/QNTM.
This development matters because it demonstrates how biopharmaceutical research can translate into practical consumer health solutions while creating value for investors. The non-dilutive nature of the funding round protects existing Quantum BioPharma shareholders, while the royalty structure ensures ongoing revenue from successful product sales. For the broader industry, this model shows how established biotech companies can spin out consumer applications while maintaining focus on their core pharmaceutical research, particularly in challenging areas like neurodegenerative and metabolic disorders where Quantum BioPharma maintains its primary research focus.
